Firstpost
  • Home
  • Video Shows
    Vantage Firstpost America Firstpost Africa First Sports
  • World
    US News
  • Explainers
  • News
    India Opinion Cricket Tech Entertainment Sports Health Photostories
  • Asia Cup 2025
Apple Incorporated Modi ji Justin Trudeau Trending

Sections

  • Home
  • Live TV
  • Videos
  • Shows
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Health
  • Tech/Auto
  • Entertainment
  • Web Stories
  • Business
  • Impact Shorts

Shows

  • Vantage
  • Firstpost America
  • Firstpost Africa
  • First Sports
  • Fast and Factual
  • Between The Lines
  • Flashback
  • Live TV

Events

  • Raisina Dialogue
  • Independence Day
  • Champions Trophy
  • Delhi Elections 2025
  • Budget 2025
  • US Elections 2024
  • Firstpost Defence Summit
Trending:
  • Charlie Kirk shot dead
  • Nepal protests
  • Russia-Poland tension
  • Israeli strikes in Qatar
  • Larry Ellison
  • Apple event
  • Sunjay Kapur inheritance row
fp-logo
Interim analysis of phase-3 trials of COVAXIN shows 78% clinical efficacy, claims Bharat Biotech
Whatsapp Facebook Twitter
Whatsapp Facebook Twitter
Apple Incorporated Modi ji Justin Trudeau Trending

Sections

  • Home
  • Live TV
  • Videos
  • Shows
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Health
  • Tech/Auto
  • Entertainment
  • Web Stories
  • Business
  • Impact Shorts

Shows

  • Vantage
  • Firstpost America
  • Firstpost Africa
  • First Sports
  • Fast and Factual
  • Between The Lines
  • Flashback
  • Live TV

Events

  • Raisina Dialogue
  • Independence Day
  • Champions Trophy
  • Delhi Elections 2025
  • Budget 2025
  • US Elections 2024
  • Firstpost Defence Summit
  • Home
  • India
  • Interim analysis of phase-3 trials of COVAXIN shows 78% clinical efficacy, claims Bharat Biotech

Interim analysis of phase-3 trials of COVAXIN shows 78% clinical efficacy, claims Bharat Biotech

FP Staff • April 21, 2021, 17:14:27 IST
Whatsapp Facebook Twitter

The efficacy rate is based on a second interim analysis of phase 3 clinical data and Bharat Biotech said that the safety and efficacy results from the final analysis will be available in June

Advertisement
Subscribe Join Us
Add as a preferred source on Google
Prefer
Firstpost
On
Google
Interim analysis of phase-3 trials of COVAXIN shows 78% clinical efficacy, claims Bharat Biotech

Bharat Biotech and ICMR announced interim results from the Phase three trials of COVAXIN. According to them, COVAXIN has shown an overall estimated clinical efficacy of 78 percent against mild, moderate, and severe COVID-19 disease and 100 percent efficacy against severe COVID-19, a press release by the Hyderabad-based company said on Wednesday. The current efficacy rate is based on a second interim analysis of phase 3 clinical research data. The vaccine’s estimated efficacy against asymptomatic COVID-19 infection to be at 70 percent, the company claimed in the statement, adding that the efficacy against severe COVID-19 disease was 100 percent (95 percent confidence interval: 60-100), with an impact on reduction in hospitalisations. The company didn’t declare the sample size considered for the phase three interim analysis, however, it said that the efficacy rate was based on accruing more than 87 symptomatic cases of COVID-19. “Due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78 percent (95 percent confidence interval: 61-88) against mild, moderate, and severe COVID-19 disease,” it added. Chairman and Managing Director of Bharat Biotech Dr Krishna Ella said, “The efficacy data against severe COVID-19 and asymptomatic infections is highly significant, as this helps reduce hospitalizations and disease transmission, respectively.” Bharat Biotech also said that the safety and efficacy results from the final analysis will be available in June, and the final report will be submitted to a peer-reviewed publication. The Phase 3 study enrolled 25,800 participants between 18-98 years of age, including 10 percent over the age of 60, with analysis conducted 14 days post the second dose. Professor Balram Bhargava, Secretary Department of Health Research & Director General, ICMR said, “I am very pleased to state that COVAXIN has shown the efficacy of 78 percent in the second interim analysis. I am also happy to note that COVAXIN works well against most variants of SARS-CoV-2.” COVAXIN, which is being manufactured by Hyderabad-based Bharat Biotech was developed with seed strains received from the National Institute of Virology, and the phase 3 clinical trial was co-funded by the Indian Council of Medical Research. “The efficacy data against severe COVID-19 and asymptomatic infections is highly significant, as this helps reduce hospitalisations and disease transmission, respectively,” said Dr Krishna Ella, chairman and managing director of Bharat Biotech. The company also said that placebo recipients have now become eligible to receive two doses of COVAXIN. Covaxin was approved and introduced initially through Emergency Use Authorization under the clinical trial mode, resulting in robust safety data in real-life conditions.

Tags
NewsTracker Vaccine Bharat Biotech lockdown ICMR coronavirus Coronavirus news coronavirus in india NIV pune Coronavirus Update COVID 19 covid 19 news COVID 19 Update severe COVID 19 COVAXIN weekend lockdown mild COVID 19 COVID 19 vaccination coronavirus vaccination COVID 19 jab COVAXIN efficacy
End of Article
Latest News
Find us on YouTube
Subscribe
End of Article

Impact Shorts

News18 SheShakti 2025: Voices of cinema, sport and music redefine nation-building

News18 SheShakti 2025: Voices of cinema, sport and music redefine nation-building

At News18 SheShakti 2025 Delhi, women from sports, cinema, and music discussed breaking barriers. Kriti Sanon and Sanya Malhotra focused on equity in cinema, Mira Erda and Ashalata Devi on sports challenges, and Kavita Krishnamurti stressed humility and perseverance for lasting success.

More Impact Shorts

Top Stories

Charlie Kirk, shot dead in Utah, once said gun deaths are 'worth it' to save Second Amendment

Charlie Kirk, shot dead in Utah, once said gun deaths are 'worth it' to save Second Amendment

From governance to tourism, how Gen-Z protests have damaged Nepal

From governance to tourism, how Gen-Z protests have damaged Nepal

Did Russia deliberately send drones into Poland’s airspace?

Did Russia deliberately send drones into Poland’s airspace?

Netanyahu ‘killed any hope’ for Israeli hostages: Qatar PM after Doha strike

Netanyahu ‘killed any hope’ for Israeli hostages: Qatar PM after Doha strike

Charlie Kirk, shot dead in Utah, once said gun deaths are 'worth it' to save Second Amendment

Charlie Kirk, shot dead in Utah, once said gun deaths are 'worth it' to save Second Amendment

From governance to tourism, how Gen-Z protests have damaged Nepal

From governance to tourism, how Gen-Z protests have damaged Nepal

Did Russia deliberately send drones into Poland’s airspace?

Did Russia deliberately send drones into Poland’s airspace?

Netanyahu ‘killed any hope’ for Israeli hostages: Qatar PM after Doha strike

Netanyahu ‘killed any hope’ for Israeli hostages: Qatar PM after Doha strike

Top Shows

Vantage Firstpost America Firstpost Africa First Sports

QUICK LINKS

  • Mumbai Rains
Latest News About Firstpost
Most Searched Categories
  • Web Stories
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Tech/Auto
  • Entertainment
  • IPL 2025
NETWORK18 SITES
  • News18
  • Money Control
  • CNBC TV18
  • Forbes India
  • Advertise with us
  • Sitemap
Firstpost Logo

is on YouTube

Subscribe Now

Copyright @ 2024. Firstpost - All Rights Reserved

About Us Contact Us Privacy Policy Cookie Policy Terms Of Use
Home Video Shorts Live TV